Patients with chronic renal failure who undergo hemodlalysis experience accelerated atherosclerosis and premature death. Since the end-metabolite, oxalic acid, accumulates In plasma In proportion to the severity of renal failure, we studied whether sodium oxalate (0 to 300 /tM) Is an endothellal toxin and, therefore, might enhance atherogenesls. Exposure to uremic levels of oxalate (>30 /JM) for 9 to 28 days depressed endothelial cell replication by 33% to 84% (mean±SD, 54%±15.7%, n=17 experiments, p=0.002.). In contrast, replication of flbroblasts exposed to 200 /iM oxalate for 45 days was not Inhibited. The Inhibitory effect of oxalate on endothellal cell replication was both dose-and time-dependent (both p<0.0001) and was first detected 3 to 7 days after the initial exposure to oxalate.